Hansoh Pharmaceutical Group Co., Ltd. is a holding company, which engages in the research and development, production, and sale of a series of pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 9,313 full-time employees. The company went IPO on 2019-06-14. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The firm mainly conducts its business in the domestic market.
03692.HK stock price ended at $40.5 on 星期三, after rising 0.55%
On the latest trading day Jan 21, 2026, the stock price of 03692.HK rose by 0.55%, climbing from $40.28 to $40.50. Throughout the session, the stock experienced a volatility of 3.82%, with prices fluctuating between a daily low of $39.26 and a high of $40.76. Alongside this price increase, trading volume also rose by 1.2M shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 4.9M shares were traded, amounting to a market value of approximately $240.8B.